LivaNova PLC (NASDAQ:LIVN) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. cut its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 17.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 830,100 shares of the company’s stock after selling 172,612 shares during the quarter. Victory Capital Management Inc.’s holdings in LivaNova were worth $42,949,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Primecap Management Co. CA grew its stake in LivaNova by 7.3% in the 3rd quarter. Primecap Management Co. CA now owns 5,785,360 shares of the company’s stock valued at $305,930,000 after acquiring an additional 395,940 shares during the last quarter. Vanguard Group Inc. grew its stake in LivaNova by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock valued at $93,612,000 after acquiring an additional 100,133 shares during the last quarter. Ameriprise Financial Inc. grew its stake in LivaNova by 96.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 916,632 shares of the company’s stock valued at $48,471,000 after acquiring an additional 449,136 shares during the last quarter. Loomis Sayles & Co. L P grew its stake in LivaNova by 31.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 879,740 shares of the company’s stock valued at $46,520,000 after acquiring an additional 208,755 shares during the last quarter. Finally, Barclays PLC grew its stake in LivaNova by 15.9% in the 3rd quarter. Barclays PLC now owns 851,870 shares of the company’s stock valued at $45,047,000 after acquiring an additional 116,842 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on LIVN shares. StockNews.com upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. Mizuho upped their target price on shares of LivaNova from $75.00 to $80.00 and gave the company a “buy” rating in a report on Thursday. Needham & Company LLC restated a “buy” rating and issued a $72.00 target price on shares of LivaNova in a report on Wednesday, May 1st. Barclays upped their target price on shares of LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Finally, Robert W. Baird upped their target price on shares of LivaNova from $58.00 to $66.00 and gave the company a “neutral” rating in a report on Thursday. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, LivaNova has an average rating of “Moderate Buy” and an average target price of $66.20.

LivaNova Trading Up 2.0 %

Shares of LIVN stock opened at $64.15 on Monday. The firm has a market cap of $3.47 billion, a P/E ratio of -106.92 and a beta of 0.92. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.36. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.17 and a quick ratio of 2.51. The firm’s 50-day simple moving average is $54.71 and its 200-day simple moving average is $51.06.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.28. The business had revenue of $294.90 million for the quarter, compared to analyst estimates of $278.17 million. LivaNova had a negative net margin of 2.68% and a positive return on equity of 13.59%. The company’s revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.43 EPS. As a group, equities analysts forecast that LivaNova PLC will post 3.01 EPS for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.